Roxadustat Market Report 2026

Roxadustat Market Overview

• Roxadustat market size has reached to $6.86 billion in 2025 • Expected to grow to $9.56 billion in 2030 at a compound annual growth rate (CAGR) of 6.9% • Growth Driver: Impact Of Rising Chronic Kidney Disease Cases On The Growth Of The Market • Market Trend: Real World Evidence Studies Strengthen Roxadustat’s Market Adoption And Reimbursement Prospects • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Roxadustat Market?

Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, leading to increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without the need for exogenous erythropoiesis-stimulating agents. It is used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production. The main types in Roxadustat are 20 mg and 50 mg. 20 mg Roxadustat is an oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor used for treating anemia associated with chronic kidney disease by stimulating endogenous erythropoietin production. The product formulation of this is oral tablets, which are distributed by various channels such as hospitals, specialty pharmacies, and dialysis centers. Roxadustat is used in chronic kidney disease-associated anemia and others.

What Is The Roxadustat Market Growth Forecast?

The roxadustat market size is expected to see strong growth in the next few years. It will grow to $9.56 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising global anemia burden, increasing preference for oral therapies, expansion of ckd patient population, growing outpatient anemia management, improved access to innovative anemia drugs. Major trends in the forecast period include rising adoption of oral anemia therapies, growing use of hif-phi drugs, increased focus on ckd-associated anemia, shift away from injectable esas, expansion of anemia treatment accessibility.

Global Roxadustat Market Segmentation

1) By Type: 20mg, 50mg 2) By Product Formulation: Oral Tablets 3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers 4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

What Is The Driver Of The Roxadustat Market?

The rising number of people with chronic kidney disease (CKD) is expected to propel the growth of the Roxadustat market going forward. Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to function properly, often leading to kidney failure if left untreated. The number of people affected by chronic kidney disease is rising globally due to factors such as aging populations, increasing rates of diabetes, hypertension, and unhealthy lifestyles. Roxadustat helps manage chronic kidney disease by stimulating the production of erythropoietin, which increases red blood cell production and helps address anemia commonly associated with the condition, thereby improving overall kidney function and quality of life for patients. For instance, in June 2023, according to the Kidney Research UK, a UK-based charity, by 2033, the number of individuals with CKD stages 3–5 is expected to rise to 3.9 million. Therefore, the rising number of people with chronic kidney disease (CKD) is driving the growth of the Roxadustat industry.

Key Players In The Global Roxadustat Market

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

Global Roxadustat Market Trends and Insights

Major companies operating in the roxadustat market are focusing on generating real world evidence, such as observational registry studies, to reinforce the long-term value, safety, and utilization patterns of their HIF PH inhibitor therapy. Real world evidence refers to clinical data collected outside controlled trials, in routine practice settings, to reflect actual patient experiences. The roxadustat market supports this trend by sponsoring large-scale real-world studies that healthcare payers and regulators increasingly rely on for evaluation. For instance, in May 2024, Astellas Pharma, a UK based company, completed the launch of the WINE study via the WiNe Registry in Germany, a non interventional cohort study capturing clinical outcomes, dosing characteristics, and hemoglobin response in patients treated with EVRENZO (roxadustat). The insights from that registry help demonstrate roxadustat’s effectiveness in real-world CKD populations and support long-term reimbursement decisions. Therefore, real-world evidence generation is driving the growth of the roxadustat market.

What Are Latest Mergers And Acquisitions In The Roxadustat Market?

In February 2024, FibroGen Inc., a US-based biopharmaceutical company, announced a partnership with Astellas Pharma Inc. and AstraZeneca PLC. With this collaboration, FibroGen Inc. aims to develop and commercialize Roxadustat for the treatment of anemia in various conditions, including chronic kidney disease (CKD) and myelodysplastic syndromes (MDS). Astellas Pharma Inc. is a Japan-based pharmaceutical company, and AstraZeneca PLC. is a UK-based pharmaceutical company involved in the development and commercialization of Roxadustat.

Regional Insights

North America was the largest region in the Roxadustat market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Roxadustat Market?

The Roxadustat market consists of sales of products such as 70 mg, 100 mg, and 150 mg film-coated tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Roxadustat Market Report 2026?

The roxadustat market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the roxadustat industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.